• EQL Pharma’s melatonin tablet Mellozzan won marketing authorization in Kazakhstan through regional partner Abdi Ibrahim.
• Approval covers the 3 mg dose; a 5 mg authorization is expected in December 2026.
• Launch of both strengths is planned for fiscal 2027/28.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EQL Pharma AB published the original content used to generate this news brief via Cision (Ref. ID: 202607150357BITN____UKPR__EN_20260715-BIT-9012-0) on July 15, 2026, and is solely responsible for the information contained therein.